BUZZ-Precision BioSciences 股价上涨,因乙肝基因编辑试验在欧洲扩大

路透中文
Apr 15
BUZZ-Precision BioSciences 股价上涨,因乙肝基因编辑试验在欧洲扩大

4月15日 -

** Precision BioSciences DTIL.O股价盘前上涨2.35%至7.40美元

** 生物技术公司表示,它已获准将法国和罗马尼亚纳入其慢性乙型肝炎试验性疗法PBGENE-HBV的ELIMINATE-B研究中

** 补充说,扩大研究的目的是在英国、美国和亚太地区现有研究机构的基础上,加快欧洲患者的注册速度

** 慢性乙型肝炎无药可治,该药物旨在针对长期肝脏感染的根本原因进行一次性治疗 - DTIL

** 补充说,选址准备工作已经开始,预计将于 2026 年第二季度进行首次患者筛查

** 公司的 PBGENE-HBV 已获得 FDA 快速通道资格

** 截至上一交易日收盘,股价年累计上涨约 74%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10